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Associations of Fibroblast Growth 
Factor 23 with parameters of  
phosphate Metabolism in Incident 
peritoneal Dialysis patients
Disorders of phosphate metabolism are common 
complications in dialyzed patients, and control of serum 
phosphorus seems to be a critical factor in the survival 
of these patients. In several studies, a tight association 
has been observed between elevated serum phosphorus 
and mortality (1,2).
Regulation of phosphate homeostasis in chronic 
kidney disease (CKD) is controlled by a variety of fac-
tors, such as phosphate loading and serum calcium, 
vitamin D and parathyroid hormone (PTH). In perito-
neal dialysis (PD), elimination of phosphate depends 
on peritoneal and renal phosphate clearance [the latter 
clearance depending on residual renal function (RRF)]. 
Recently, high serum levels of fibroblast growth fac-
tor 23 (FGF-23) have been regarded as independent 
factor associated with morbidity and mortality in dia-
lyzed patients (3–6). In patients with CKD, circulating 
FGF-23 gradually increases with declining renal func-
tion. Isakova et al. (7) suggested that FGF-23 might be 
a sensitive early biomarker of disordered phosphorus 
metabolism in patients with CKD and a normal phos-
phate level, because FGF-23 increases earlier than either 
phosphate or PTH. However, the clinical significance of 
FGF-23 measurement in PD patients has not yet been 
fully established.
A recent study of ours (8) suggests that serum phos-
phate may be associated with peritoneal membrane 
transport in incident PD patients. The aim of the present 
study, conducted in a larger cohort of subjects, was to 
more thoroughly evaluate associations between regula-
tors of phosphate metabolism (including FGF-23) and 
phosphate concentrations and clearances at the onset 
of PD.
METHODS
At the Peritoneal Dialysis Center, Department of 
Nephrology, Transplantology and Internal Medicine, 
Szczecin, Poland, 50 patients were started on con-
tinuous ambulatory PD using 4 daily exchanges of 
1.5 – 2 L glucose-based dialysate with a calcium con-
centration of 1.25 mmol/L (Baxter Healthcare SA, 
Castlebar, Ireland). All patients gave written informed 
consent, and the study was approved by the local bio-
ethics committee. Peritoneal and renal clearances of 
creatinine and phosphorus were calculated by means 
of direct determination from dialysis fluids, urine, 
and serum. Serum levels of FGF-23 were determined 
using a sandwich enzyme-linked immunosorbent assay 
(Human FGF-23 ELISA Kit: Millipore Corporation, 
Bedford, MA, USA).
Table 1 presents the main characteristics of the study 
group. The causes of end-stage renal disease were dia-
betes (n = 6), glomerulonephritis (n = 12), hypertension 
(n = 10), chronic pyelonephritis (n = 3), other (n = 10), 
and unknown (n = 9).
The Spearman rank correlation coefficient (Rs) was 
used to measure associations between quantitative vari-
ables. The Mann–Whitney test was used to compare values 
between groups. A general linear model was used for the 
multivariate analysis. Variables with non-normal distri-
butions (serum FGF-23 and phosphorus), as evidenced by 
a Shapiro–Wilks test, were transformed logarithmically 
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before the general linear model analysis. Values of p < 
0.05 were considered statistically significant.
RESULTS
Hyperphosphatemia (that is, a phosphorus level 
> 1.8 mmol/L) was present in 28% of patients. Calcium 
and vitamin D supplementation were not significantly 
associated with serum calcium, phosphorus, PTH, or 
FGF-23.
We observed a strong positive correlation between 
serum phosphorus and FGF-23 (Rs = 0.54, p = 0.00085, 
Figure 1). Table 2 presents the associations of serum 
phosphorus, PTH, and FGF-23 with parameters of PD and 
RRF in patients at the onset of PD.
Renal phosphate clearance was strongly negatively 
correlated with serum phosphorus (Rs = –0.51, p = 0.003), 
but not with serum FGF-23 (Rs = –0.26, p = 0.19).
Multivariate analysis using the log of serum FGF-23 as 
the dependent variable and the log of serum phosphate 
and the RRF as independent variables showed that, in 
patients at the onset of PD, a high phosphate concen-
tration is an independent determinant of high serum 
FGF-23 (β = 0.53, p = 0.0028), independent of low RRF 
(β = –0.15, p = 0.36).
TABLE 1 
Characteristics of the Study Population
  Variable Value
Patients (n) 50
Mean age (years) 45.6±16.9
Sex [n (%)] 
 Men 28 (56)
 Women 22 (44)
Use of [n (%)] 
 Calcium phosphate binders 35 (70)
 Alpha-calcidiol 36 (72)
RRF (mL/min/1.73 m2) 9.3±4.7
Diuresis (mL/d) 1934±1110
Weekly phosphate clearance (L) 
 Renal 66.9±43.2
 Peritoneal 35.6±8.9
Weekly peritoneal CCr (L) 39.3±8.8
D/P creatinine in PET 0.66±0.12
Hemoglobin (mmol/L) 7.2±0.8
Hematocrit (%) 34.0±3.9
Serum concentration of 
 Albumin (g/L) 37.8±4.5
 C-Reactive protein (mg/L) 9.5±14.7
 Urea (mg/dL) 94.1±32.5
 Creatinine (mg/dL) 5.5±2.3
 Total calcium (mmol/L) 2.2±0.2
 Phosphorus (mmol/L) 1.4±0.4
 iPTH (pg/mL) 457±309
 FGF-23 (pg/mL) 557±856
RRF = residual renal function; CCr = creatinine clearance; D/P = 
dialysate-to-plasma ratio; PET = peritoneal equilibration test; 
iPTH = intact parathyroid hormone; FGF-23 = fibroblast growth 
factor 23.
Figure 1 — Correlation between serum concentrations of 
phosphorus (P) and fibroblast growth factor 23 (FGF23) 
in incident PD patients. Both variables are logarithmically 
transformed (Ln).
TABLE 2 
Associationsa of Selected Serum Concentrations with 
Parameters of Peritoneal Dialysis and Residual  
Renal Function at Peritoneal Dialysis Onset
 Serum concentrations of
  P FGF-23 iPTH Ca
  Parameter (mmol/L) (pg/mL) (pg/mL) (mmol/L)
RRF (mL/min/ 
 1.73 m2) 
–0.43b –0.42c –0.03 0.27
Diuresis (mL/d) –0.29c –0.21 0.06 0.17
Weekly clearance (L)    
 Renal, P –0.51b –0.26 –0.15 0.10
 Peritoneal, P –0.27 –0.06 0.12 –0.07
 Peritoneal, Cr 0.17 0.29 0.05 –0.16
Serum P (mmol/L) — 0.54b 0.29c 0.00
P = phosphate; FGF-23 = fibroblast growth factor 23; iPTH = 
intact parathyroid hormone; RRF = residual renal function; 
Cr = creatinine.
a As Spearman ρ coefficients.
b p < 0.01.
c p < 0.05.
This single copy is for your personal, non-commercial use only. 
For permission to reprint multiple copies or to order presentation-ready 
copies for distribution, contact Multimed Inc. at marketing@multi-med.com.
449
PDI july 2013 – Vol. 33, No. 4 SHORT REPORTS
DISCUSSION
Of PD patients overall, 40% – 50% are estimated 
to have serum phosphate concentrations exceeding 
1.8 mmol/L (9). In the present study, the prevalence 
of hyperphosphatemia was 28%, which is consistent 
with a study of 264 continuous ambulatory PD patients 
by Bernardo et al. (10) in which the prevalence 
reached 30% and, after 1 year of PD treatment, serum 
phosphate correlated negatively with RRF and renal 
phosphate clearance. We also observed negative cor-
relations between serum phosphorus and renal phos-
phate clearance, which may underline the important 
role of RRF in phosphate metabolism at the beginning of 
PD therapy.
The main physiologic role of FGF-23 in healthy subjects 
is to increase urinary phosphate excretion to maintain 
stable levels of serum phosphate. The increase in FGF-23 
starts at a very early stage of CKD in an attempt to stabi-
lize serum phosphate as the number of intact nephrons 
declines. Several studies showed that increased serum 
FGF-23 was associated with increased cardiovascular risk 
and mortality in dialyzed patients (3,11). In a group of 
patients starting hemodialysis, Gutiérrez et al. (11) found 
a strong relationship between high serum FGF-23 and an 
increased risk for 1-year mortality. Interestingly, in that 
population, FGF-23 was a stronger predictor of mortal-
ity than serum phosphorus was. Other studies showed 
that serum FGF-23 is related to the prevalence of left 
ventricular hypertrophy in patients with CKD (12,13). 
In a study by Faul et al. (14), the authors reported 
that serum FGF-23 was independently associated with 
left ventricular hypertrophy in a large, racially diverse 
CKD cohort. Interestingly, studies on mice disclosed 
that the pathogenesis of left ventricular hypertrophy 
attributable to the action of FGF-23 had a klotho-
independent mechanism.
In the PD patient population, data on FGF-23 are 
scarce. In a study by Isakova et al. (15), performed in 
67 adult PD patients, the authors found that longer 
dialysis vintage (R = 0.31), lesser RRF (R = –0.37), and 
lower renal phosphate clearance (R = –0.38) were asso-
ciated with higher levels of serum FGF-23. In a study 
performed in 35 incident PD patients, Viaene et al. (16) 
showed that declining renal function was inversely cor-
related with serum FGF-23. Those authors also observed 
a significant increase in serum phosphorus with the 
decline of RRF.
In the present study of incident PD patients, we found 
strong correlations between FGF-23 and RRF and between 
FGF-23 and serum phosphorus. Moreover, in multivariate 
analysis, we found that a high phosphorus concentration 
was a significant predictor of high FGF-23, independent 
of RRF. It seems possible that increased serum phospho-
rus is directly responsible for increased serum FGF-23, 
and that the influence of RRF is indirect (mediated by 
an increased phosphorus concentration). In our study, 
neither renal nor peritoneal phosphate clearance was 
associated with serum FGF-23, potentially suggesting 
that the influence of phosphate elimination on FGF-23 in 
incident PD patients is also indirect (mediated by serum 
phosphorus concentration).
To the best of our knowledge, we are the first to report 
the strong association between serum phosphorus and 
FGF-23, independent of RRF, in incident PD patients. 
Because increased serum FGF-23 can be independently 
associated with higher morbidity and mortality, it seems 
that, even in a group of incident PD patients without 
marked hyperphosphatemia, control of serum phosphate 
may bring benefits and improve outcomes.
CONCLUSIONS
Our study highlights the strong positive association 
between serum phosphorus and FGF-23 in patients at the 
start of PD therapy. This relationship is independent of 
RRF. Moreover, renal and peritoneal phosphate elimina-
tion are not associated with serum FGF-23. Because, by 
itself, increased FGF-23 may be associated with increased 
morbidity, further studies of FGF-23 as a potential target 
for clinical intervention are awaited.
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prevalence and Factors Associated with 
hypomagnesemia in Southern Chinese 
Continuous Ambulatory peritoneal 
Dialysis patients
KEY WORDS: Continuous ambulatory peritoneal 
dialysis; hypomagnesemia; malnutrition; hypertonic 
peritoneal dialysate.
Magnesium (Mg2+) is a metal element that is essential 
for life. It is involved in hundreds of enzymatic reac-
tions, and it is an important cofactor in many biologic 
processes. Profound magnesium deficiency results in a 
variety of clinical manifestations, including a positive 
Chvostek sign or Trousseau sign, vertigo, nystagmus, 
tetany, cardiac arrhythmia, and bone instability (1). 
However, hypomagnesemia has been paid little atten-
tion in the continuous ambulatory peritoneal dialysis 
(CAPD) population.
Patients on CAPD dialyzed with peritoneal dialysate 
containing 0.25 mol/L magnesium were reported to 
develop a considerable fall in serum magnesium (2); 
however, the causes of hypomagnesemia are far more 
complicated. Hypertonic exchanges, different daily peri-
toneal dialysis (PD) exchange volumes, comorbidities, 
and nutrition status can also affect magnesium balance in 
this population. The present study was therefore designed 
to investigate the prevalence of hypomagnesemia and its 
associated factors in CAPD patients.
METHODS
Patient Selection and Clinical Information: This cross-
sectional survey study enrolled prevalent CAPD patients 
at the PD center of The First Affiliated Hospital of Sun 
 Yat-sen University from February to June 2011. All patients 
had received CAPD treatment for more than 1 month and 
were being regularly followed. Patients were dialyzed 
with a low-magnesium dextrose peritoneal dialysate 
(containing Mg2+ 0.25 mmol/L, Ca2+ 1.25 mmol/L or 
1.77 mmol/L, Na+ 132 mmol/L, Cl– 96 mmol/L) produced 
by Baxter Healthcare (Guangzhou, China).
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